Last reviewed · How we verify
BioChaperone PDGF-BB
BioChaperone PDGF-BB is a Growth factor Small molecule drug developed by Adocia. It is currently in Phase 3 development for Chronic diabetic foot ulcers, Chronic wounds.
BioChaperone PDGF-BB is a formulation of platelet-derived growth factor BB designed to enhance wound healing and tissue repair by promoting angiogenesis and cell proliferation.
BioChaperone PDGF-BB is a protein-based drug that acts as an agonist to the platelet-derived growth factor receptor. It is being studied for the treatment of diabetic foot ulcers, with clinical trials comparing its efficacy to Regranex (becaplermin gel) in this indication.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BioChaperone PDGF-BB |
|---|---|
| Sponsor | Adocia |
| Drug class | Growth factor |
| Target | PDGF receptor (PDGFR) |
| Modality | Small molecule |
| Therapeutic area | Wound Care / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
PDGF-BB is a naturally occurring growth factor that stimulates fibroblast and smooth muscle cell proliferation and migration, promoting new blood vessel formation and extracellular matrix deposition. The BioChaperone technology platform from Adocia uses proprietary formulation approaches to improve the stability, bioavailability, and therapeutic efficacy of PDGF-BB, enabling better tissue regeneration in chronic wounds and other conditions requiring enhanced healing responses.
Approved indications
- Chronic diabetic foot ulcers
- Chronic wounds
Common side effects
- Application site reactions
- Infection
- Hypergranulation
Key clinical trials
- A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer (PHASE3)
- Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BioChaperone PDGF-BB CI brief — competitive landscape report
- BioChaperone PDGF-BB updates RSS · CI watch RSS
- Adocia portfolio CI
Frequently asked questions about BioChaperone PDGF-BB
What is BioChaperone PDGF-BB?
How does BioChaperone PDGF-BB work?
What is BioChaperone PDGF-BB used for?
Who makes BioChaperone PDGF-BB?
What drug class is BioChaperone PDGF-BB in?
What development phase is BioChaperone PDGF-BB in?
What are the side effects of BioChaperone PDGF-BB?
What does BioChaperone PDGF-BB target?
Related
- Drug class: All Growth factor drugs
- Target: All drugs targeting PDGF receptor (PDGFR)
- Manufacturer: Adocia — full pipeline
- Therapeutic area: All drugs in Wound Care / Regenerative Medicine
- Indication: Drugs for Chronic diabetic foot ulcers
- Indication: Drugs for Chronic wounds
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing